Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $576,000.

  • Aytu Biopharma's Share-based Compensation fell 34.10% to $114,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $517,000, marking a year-over-year decrease of 76.02%. This contributed to the annual value of $576,000 for FY2025, which is 80.23% down from last year.
  • Per Aytu Biopharma's latest filing, its Share-based Compensation stood at $576,000 for FY2025, which was down 80.23% from $2.9 million recorded in FY2024.
  • Aytu Biopharma's Share-based Compensation's 5-year high stood at $6.0 million during FY2023, with a 5-year trough of $576,000 in FY2025.
  • Its 3-year average for Share-based Compensation is $3.2 million, with a median of $2.9 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 231.23% in 2021, then plummeted by 80.23% in 2025.
  • Aytu Biopharma's Share-based Compensation (Yearly) stood at $3.6 million in 2021, then surged by 46.84% to $5.2 million in 2022, then climbed by 15.21% to $6.0 million in 2023, then crashed by 51.82% to $2.9 million in 2024, then slumped by 80.23% to $576,000 in 2025.